ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by ADMA Biologics, Inc. on February 5, 2015, reporting events that occurred on January 30, 2015. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation approvals.
Material Changes
The Board of Directors approved the following compensation adjustments effective for the 2015 fiscal year and retroactively for 2014:
- 2015 Base Salaries:
- Brian Lenz: $350,000
- Dr. James Mond: $350,000
- Adam S. Grossman: $480,000
- 2014 Bonuses:
- Brian Lenz: $123,200
- Dr. James Mond: $125,125
- Adam S. Grossman: $247,500
- Equity Grants: The Board approved the grant of options to purchase common stock consistent with prior determinations.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the compensation approvals.
Investor Verification Points
- Verify the total cash compensation impact of the approved 2014 bonuses and 2015 salary increases.
- Review the specific terms and vesting schedules of the newly approved stock options.
- Confirm the roles and titles of Brian Lenz, Dr. James Mond, and Adam S. Grossman to assess the significance of the compensation relative to their responsibilities.